Cellular Senescence Secretome Biomarkers in Human Aging

Abstract

Cellular senescence is a fundamental biological process implicated in aging and age-related diseases. The secretome of senescent cells, termed the senescence-associated secretory phenotype (SASP), encompasses a diverse array of cytokines, chemokines, growth factors, and proteases. These secreted factors serve as potential biomarkers for biological aging and contribute to the pathogenesis of several chronic conditions. This review critically examines the current evidence on SASP components as biomarkers of cellular senescence in human aging, elucidates their mechanistic roles, assesses clinical relevance, and discusses recent advances and guideline recommendations for their application in clinical practice.

Introduction

Aging is a complex, multifactorial process characterized by a progressive decline in physiological integrity, leading to impaired function and increased vulnerability to disease. Cellular senescence, defined as a stable cell cycle arrest in response to various stressors, is a key hallmark of aging. Accumulation of senescent cells in tissues is associated with both tissue dysfunction and the development of age-associated diseases. Senescent cells secrete a distinct set of bioactive molecules collectively referred to as the senescence-associated secretory phenotype (SASP). Understanding the profiles and clinical utility of SASP components as biomarkers is crucial for advancing diagnostic and therapeutic strategies targeting aging and its related pathologies.

Epidemiology / Disease Burden

The global population is aging rapidly, with the proportion of individuals aged 65 and older projected to double by 2050. This demographic shift is accompanied by a parallel rise in the prevalence of age-related diseases such as cardiovascular disease, cancer, diabetes, and neurodegenerative disorders. Senescent cell accumulation and SASP activity have been implicated in the pathogenesis of these conditions, highlighting the potential of senescence biomarkers to inform population health strategies and individualized risk assessment.

Pathophysiology

Cellular senescence can be triggered by diverse stressors including telomere attrition, DNA damage, oncogene activation, oxidative stress, and mitochondrial dysfunction. Senescent cells remain metabolically active and exhibit a SASP characterized by the secretion of pro-inflammatory cytokines (e.g., IL-6, IL-8), matrix metalloproteinases (e.g., MMP-1, MMP-3), growth factors (e.g., VEGF), and other molecules. These SASP components reinforce senescence via autocrine and paracrine signaling, promote chronic inflammation, and alter the tissue microenvironment, thereby contributing to tissue dysfunction and disease progression. The complex interplay between the SASP and the immune system also influences the clearance or persistence of senescent cells in tissues.

Risk Factors

Multiple intrinsic and extrinsic factors modulate the induction and accumulation of cellular senescence. Intrinsic factors include genetic predisposition, telomere length, and DNA repair capacity. Extrinsic factors encompass environmental exposures (e.g., ultraviolet radiation, toxins), lifestyle variables (e.g., diet, smoking, physical inactivity), and chronic diseases (e.g., metabolic syndrome, chronic infections). These risk factors not only accelerate senescence but also influence the qualitative and quantitative composition of the SASP, which may vary according to cell type, tissue, and the nature of the senescence-inducing insult.

Clinical Features

While cellular senescence is a subcellular phenomenon, its systemic effects manifest clinically as features of biological aging and contribute to the pathogenesis of age-related diseases. Elevated circulating levels of SASP factors, such as IL-6, IL-8, and CCL2, have been correlated with frailty, cognitive decline, sarcopenia, and increased morbidity and mortality in elderly populations. Furthermore, the tissue-specific burden of senescent cells and their secretome may underlie the clinical heterogeneity observed in geriatric syndromes.

Diagnosis

Detection and quantification of senescence and SASP biomarkers in human samples are emerging as valuable tools for assessing biological aging. Biomarkers such as p16^INK4a expression, SA-β-gal activity, and DNA damage foci are used in research settings, but their clinical translation is limited. Circulating SASP factors, including IL-6, IL-8, MCP-1, MMPs, and GDF15, are measurable in plasma or serum and have shown promise as minimally invasive biomarkers of senescence. Omics-based approaches, including proteomics and transcriptomics, are further refining SASP profiling and enabling the identification of novel biomarkers with improved specificity and sensitivity.

Treatment & Management

There are currently no approved therapies that specifically target cellular senescence in clinical practice. However, interventions that modulate the SASP or selectively eliminate senescent cells (senolytics) are being investigated in preclinical and early-phase clinical studies. Lifestyle modifications such as caloric restriction, exercise, and pharmacological agents like metformin and rapamycin have demonstrated potential in attenuating senescence-associated inflammation and SASP activity. The application of SASP biomarker profiling may eventually enable the stratification of patients for individualized therapeutic interventions aimed at reducing senescent cell burden and improving healthspan.

Recent Advances / Emerging Therapies

Significant advances have been made in the development of senolytic drugs (e.g., dasatinib, quercetin, navitoclax) and SASP modulators (e.g., JAK inhibitors) that target the detrimental effects of the senescent secretome. Early clinical trials have demonstrated the feasibility and safety of senolytic approaches in conditions such as idiopathic pulmonary fibrosis, diabetic kidney disease, and osteoarthritis. High-throughput omics technologies have expanded our understanding of the SASP, uncovering new biomarker candidates with potential prognostic and predictive value. Integration of SASP biomarker panels into clinical research is poised to transform the landscape of geriatric medicine and age-related disease management.

Guideline Recommendations

While the clinical application of senescence and SASP biomarkers is still evolving, recent consensus statements from geriatric and aging research societies emphasize the need for standardized biomarker assays, robust validation in diverse populations, and longitudinal studies to establish clinical utility. Guidelines recommend the incorporation of validated biomarkers in clinical trials for aging interventions and advocate for multidisciplinary collaboration to accelerate biomarker discovery and implementation in clinical practice.

Conclusion

Cellular senescence and its secretome represent a paradigm shift in our understanding of human aging and the pathophysiology of age-related diseases. SASP biomarkers offer a promising avenue for the assessment of biological aging, risk stratification, and targeted therapeutic interventions. Ongoing research, technological innovations, and standardized guidelines are crucial to realizing the full clinical potential of senescence secretome biomarkers and advancing precision medicine in the context of aging.